300 related articles for article (PubMed ID: 25242766)
1. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
[TBL] [Abstract][Full Text] [Related]
2. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
3. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.
Caires RA; Marques ID; Repizo LP; Sato VA; Carmo LP; Machado DJ; de Paula FJ; Nahas WC; David-Neto E
Transplant Proc; 2012 Oct; 44(8):2388-90. PubMed ID: 23026601
[TBL] [Abstract][Full Text] [Related]
4. Interstitial Lung Disease After Kidney Transplantation and the Role of Everolimus.
Solazzo A; Botta C; Nava F; Baisi A; Bonucchi D; Cappelli G
Transplant Proc; 2016 Mar; 48(2):349-51. PubMed ID: 27109953
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitors in pediatric liver transplant recipients.
Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
[TBL] [Abstract][Full Text] [Related]
6. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
7. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
[TBL] [Abstract][Full Text] [Related]
8. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
12. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile and outcomes of
Saikumar Doradla LP; Lal H; Kaul A; Bhaduaria D; Jain M; Prasad N; Thammishetti V; Gupta A; Patel M; Sharma RK
Saudi J Kidney Dis Transpl; 2020; 31(1):160-168. PubMed ID: 32129209
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
[TBL] [Abstract][Full Text] [Related]
16. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
van Dijk M; van Roon AM; Said MY; Bemelman FJ; Homan van der Heide JJ; de Fijter HW; de Vries APJ; Bakker SJL; Sanders JSF
Transpl Int; 2018 Dec; 31(12):1380-1390. PubMed ID: 30106185
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
[TBL] [Abstract][Full Text] [Related]
18. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
